Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. by Inomata Minehiko et al.
MOLECULAR AND CLINICAL ONCOLOGY  4:  774-778,  2016774
Abstract. Treatment with epidermal growth factor 
receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been 
shown to prolong survival in patients with EGFR muta-
tion-positive non-small cell lung cancer (NSCLC). The present 
study performed a retrospective analysis to investigate the 
association between the plasma lactate dehydrogenase (LDH) 
levels and survival in patients with EGFR mutation-positive 
NSCLC receiving treatment with EGFR-TKIs. The medical 
charts of patients with EGFR mutation-positive NSCLC 
who were receiving treatment with EGFR-TKIs at Toyama 
University Hospital between 2007 and 2014 were assessed. 
The data from 65 patients were included in the analysis. 
Patients with higher plasma LDH levels exhibited shorter 
progression-free survival (6.2 vs. 13.2 months; P<0.01) 
and overall survival (10.5 vs. 36.1 months; P<0.01) periods 
compared with patients with lower plasma LDH levels. A 
Cox proportional hazards model identified that the plasma 
LDH level was associated with the progression-free survival 
(P=0.05) and overall survival (P<0.01). An association was 
demonstrated between the pretreatment plasma LDH level 
and the survival in patients with EGFR mutation-positive 
NSCLC receiving treatment with EGFR-TKIs. Close observa-
tion is required in EGFR mutation-positive NSCLC patients 
exhibiting high plasma LDH levels following the initiation of 
treatment with EGFR-TKIs.
Introduction
Lung cancer is a leading cause of mortality world-
wide. Although treatment with epidermal growth factor 
receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been 
reported to prolong the survival in patients with EGFR muta-
tion-positive non-small cell lung cancer (NSCLC) (1-3), the 
survival period varies widely in individual patients receiving 
EGFR-TKI treatment.
Our previous study reported the existence of an association 
between the pre‑treatment plasma neuron‑specific enolase level 
and the patient survival in EGFR mutation-positive NSCLC 
patients initiated on gefitinib treatment (4). Neuron‑specific 
enolase is a marker of neuroendocrine tumors, including 
small cell lung cancer, and functions as a glycolytic enzyme. 
Lactate dehydrogenase (LDH), also an enzyme contributing 
to anaerobic glycolysis, has been reported as a prognostic 
factor in patients with various malignant tumors, including 
lung cancer (5-8). The association between the plasma LDH 
level and tumor hypoxia is considered as one of the mecha-
nisms underlying this linkage (6-8). However, the impact of 
the pre-treatment plasma LDH level on the survival in patients 
with EGFR mutation-positive NSCLC receiving treatment 
with EGFR-TKIs remains to be elucidated.
For patients with lung cancer initiated on treatment with 
EGFR-TKIs, investigation of the prognostic factors and iden-
tification of patients with a poor prognosis are important for 
planning the appropriate follow-up schedule, and may also 
contribute to the establishment of novel treatment strategies. 
The present study performed a retrospective analysis to 
investigate the association between the plasma LDH levels and 
survival in EGFR mutation-positive NSCLC patients receiving 
treatment with EGFR-TKIs.
Patients and methods
Patient selection and evaluation. The present study retrospec-
tively reviewed the medical charts of patients with lung cancer 
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receiving treatment at Toyama University Hospital (Toyama, 
Japan) between 2007 and 2014. The inclusion criteria were as 
follows: i) Cytologically or histologically confirmed NSCLC; 
ii) tumor positive for EGFR gene mutations, with the exception 
of the T790M mutation; iii) patients receiving treatment with 
EGFR-TKIs. Patients with a previous history of treatment with 
EGFR-TKIs were excluded from the analysis.
The following patient data was collected: Age, gender, 
number of treatment regimens received previously, disease 
stage, tumor EGFR mutation status, patient performance 
status (PS), smoking history and presence/absence of distant 
metastasis. Exon 19 deletions and the exon 21 point mutation 
of L858R in the EGFR gene were classified as common muta-
tions, while any other mutations were classified as uncommon 
mutations. The disease stage was classified as stage III/IV or 
postoperative recurrence. Presence/absence of metastatic lesions 
was determined by imaging examinations, including computed 
tomography, magnetic resonance imaging and/or scintigraphy, 
regardless of the cytological or histological findings. The present 
study was performed with the approval of the Ethics Committee 
of the University of Toyama (approval no. 26-158).
Statistical analysis. Survival curves were drawn according to 
the Kaplan-Meier method. Progression-free survival (PFS) was 
calculated from the date on which the EGFR-TKI administra-
tion was initiated until the date on which disease progression 
was first documented or the date of mortality due to any cause, 
and censored at the last visit at which no disease progression was 
observed. The overall survival (OS) was calculated from the date 
on which the EGFR-TKI administration was initiated until the 
date of mortality due to any cause, and censored at the last visit 
at which the patient remained alive. The association between 
the survival and the patient clinical characteristics was analyzed 
by the log-rank test. With regards to the analysis regarding the 
LDH level, the patients were dichotomized into two groups, 
according to the median LDH level. The independent associa-
tion between each variable and the survival were analyzed using 
a Cox proportional hazards model. The variables with a P-value 
<0.2 by the log-rank test were entered as independent variables 
into the Cox proportional hazards model.
Results
Patient characteristics. Table I lists the patient characteristics. 
A total of 65 patients fulfilled the criteria and were included 
in the analysis. Of these, 41 patients who were receiving 
treatment with gefitinib were also enrolled into our previous 
study (4). Female patients were slightly dominant, accounting 
for 53.8% of the population. The median (range) age of the 
patients was 68 (49-87) years, and 52.3% were <70-years-old. 
The majority of the patients were treated with gefitinib 
and 28.5% of patients were treated with erlotinib. The majority 
of patients (90.8%) exhibited tumors harboring common 
EGFR gene mutations. The plasma LDH levels ranged 
between 118 and 1,680 IU/l (median value, 208 IU/l). Disease 
stage, PS, smoking history, liver metastases and pleural effu-
sion were imbalanced between the two groups.
Survival. Fig. 1 reveals the Kaplan-Meier survival curves for 
the PFS and OS in the patient groups divided by the plasma 
LDH level of 210 IU/l. Significant differences in the PFS 
(6.2 vs. 13.2 months; P<0.01) and OS (10.5 vs. 36.1 months; 
P<0.01) were observed between the high-LDH and low-LDH 
groups.
The log-rank test revealed that the P-values for the 
disease stage (P=0.02), EGFR mutation status (P=0.17), PS 
(P=0.01), presence/absence of brain metastasis (P<0.01), pres-
ence/absence of liver metastasis (P=0.10), presence/absence of 
pleural effusion (P=0.12) and the plasma LDH level (P<0.01) 
were determined to be <0.2, and these variables were entered 
into the Cox proportional hazards model as independent 
variables. The P-value for gender (P=0.37), age (P=0.25), type 
of EGFR-TKI (P=0.60), number of previous treatment regi-
mens (P=0.91), smoking history (P=0.43), presence/absence 
of metastasis to the lung (P=0.83), bone (P=0.90) and adrenal 
gland (P=0.95) were >0.2. Table II shows the results of the 
analysis performed using the Cox proportional hazards model 
to assess the association between each variable and the PFS. 
The analysis identified that the EGFR status (P=0.03), pres-
ence/absence of brain metastasis (P<0.01) and the plasma 
LDH level (P=0.05) were associated with the PFS.
With regards to the OS, the P-values for the disease stage 
(P=0.07), EGFR mutation status (P=0.07), PS (P<0.01), pres-
ence/absence of pleural effusion (P=0.01) and plasma LDH 
level (P<0.01) were <0.2, and these were entered into the Cox 
proportional hazards model as independent variables. The 
P-value for gender (P=0.29), age (P=0.94), type of EGFR-TKI 
(P=0.80), number of previous treatment regimens (P=0.46), 
smoking history (P=0.62), and the presence/absence of metas-
tasis to the brain (P=0.34), liver (P=0.36), lung (P=0.61), bone 
Figure 1. Kaplan-Meier curve for each patient group divided according to the 
plasma LDH level (solid line, LDH <210; dashed line, LDH ≥210). The patient 
group with a higher plasma LDH level had (A) shorter PFS (P<0.01) and 
(B) OS (P<0.01) periods. LDH, lactate dehydrogenase; PFS, progression-free 
survival; OS, overall survival.
  A
  B
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(P=0.66) and adrenal gland (P=0.93) were >0.2. Table III 
shows the results of the analysis performed using the Cox 
proportional hazards model to assess the association between 
each variable and the OS. The analysis identified that the 
EGFR status (P<0.01), PS (P=0.03) and plasma LDH level 
(P<0.01) were associated with the OS.
Table I. Patient characteristics.
 All patients LDH low LDH high
Characteristic (n=65) (n=35) (n=30)
Gender, n (%)
  Male 30 (46.2) 19 (54.3) 11 (36.7)
  Female 35 (53.8) 16 (45.7) 19 (63.3)
Age, n (%)
  <70 34 (52.3) 18 (51.4) 16 (53.3)
  ≥70 31 (47.7) 17 (48.6) 14 (46.7)
EGFR-TKI, n (%)
  Gefitinib 53 (81.5) 28 (80.0) 25 (83.3)
  Erlotinib 12 (28.5) 7 (20.0) 5 (16.7)
Prior regimen, n (%)
  0 49 (75.4) 25 (71.4) 24 (80.0)
  ≥1 16 (24.7) 10 (28.6) 6 (20.0)
Stage, n (%)
  III/IV 50 (76.9) 23 (65.7) 27 (90.0)
  Recurrence 15 (23.1) 12 (34.3) 3 (10.0)
EGFR status, n (%)
  Common 59 (90.8) 31 (88.6) 28 (93.3)
  Uncommon 6 (9.2) 4 (11.4) 2 (6.7)
PS, n (%)
  0-1 45 (69.2) 27 (77.1) 18 (60.0)
  ≥2 20 (30.8) 8 (22.9) 12 (40.0)
Smoking history, n (%)
  Yes 31 (47.7) 20 (57.1) 11 (36.7)
  No 34 (52.3) 15 (42.9) 19 (63.3)
Brain metastases, n (%)
  Yes 19 (29.2) 10 (28.6) 9 (30.0)
  No 46 (70.8) 25 (71.4) 21 (70.0)
Liver metastasis, n (%) 
  Yes 14 (21.5) 4 (11.4) 10 (33.3)
  No 51 (78.5) 31 (88.6) 20 (66.7)
Lung metastasis, n (%)
  Yes 25 (38.5) 12 (34.3) 13 (43.3)
  No 40 (61.5) 23 (65.7) 17 (56.7)
Adrenal gland metastasis, n (%)
  Yes 5 (7.7) 2 (5.7) 3 (10.0)
  No 61 (92.3) 33 (94.3) 27 (90.0)
Bone metastasis, n (%)
  Yes 31 (47.7) 15 (42.9) 16 (53.3)
  No 34 (52.3) 20 (57.1) 14 (46.7)
Pleural effusion, n (%)
  Yes 30 (46.2) 10 (28.6) 20 (66.7)
  No 35 (53.8) 25 (71.4) 10 (33.3)
LDH, lactate dehydrogenase; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase; PS, performance status.
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Post‑progression treatment. In the higher LDH group, 27 patients 
experienced disease progression, 4 (14.8%) patients were treated 
with EGFR-TKI re-administration, 5 (18.5%) were treated with 
platinum doublet chemotherapy and 5 (18.5%) were treated with 
single cytotoxic agent. In the lower LDH group, 25 patients 
experienced disease progression, 3 (12.0%) were treated with 
EGFR-TKI re-administration, 5 (20.0%) were treated with 
platinum doublet chemotherapy and 4 (16.0%) were treated with 
a single cytotoxic agent.
Discussion
The present study revealed the existence of a significant associa-
tion between the pre-treatment plasma LDH level and survival 
in patients with EGFR mutation-positive NSCLC receiving 
treatment with EGFR-TKIs. Elevated plasma LDH has been 
reported to be associated with a poor prognosis in patients with 
several types of malignancies, including lung cancer, receiving 
various treatments (5-8). Based on these previous reports, it was 
considered that the plasma LDH level may serve as a prognostic 
factor in patients with EGFR mutation-positive NSCLC.
Several mechanisms underlying the association between the 
serum LDH level and the patient survival have been proposed. 
LDH is a glycolytic enzyme that contributes to anaerobic 
production of adenosine triphosphate, and the increased 
production of LDH can be a direct marker of severe tumor 
hypoxia. LDH-5, one of the isoenzymes of LDH, is induced 
by hypoxia-inducible factor-1α in the hypoxic environment of 
the tumor; therefore, high plasma LDH may reflect an upregu-
lated hypoxia inducible factor-1α-molecular cascade (7,8). 
Findings lending support to the above-mentioned mechanisms 
were reported by Koukourakis et al (7) who demonstrated 
that the tumor LDH-5 expression was associated with that 
of hypoxia-inducible factor and vascular endothelial growth 
factor. In addition, LDH activity results in acidification of 
the extracellular space through the production of lactic acid, 
which may be associated with an increased invasive ability 
and angiogenic capability of tumors (6-8).
It is possible that the association between plasma LDH 
level and survival demonstrated in the present study partly 
resulted from the activity of VEGF. The additional efficacy of 
bevacizumab on erlotinib in patients with NSCLC harboring 
EGFR gene mutation (9) suggests that VEGF activity influ-
ences patient survival or efficacy of EGFR‑TKI, although the 
association between VEGF expression and the patient survival 
treated with EGFR-TKI remains to be elucidated.
The present study was retrospective in nature and the 
sample size was small. Although multivariate analyses were 
performed, it may be difficult to completely exclude the 
possible existence of confounding factors affecting patient 
survival. Furthermore, it was not confirmed whether the 
plasma LDH level may be a predictive factor due to the small 
sample size and retrospective design of this study.
In conclusion, the results of the present study indicated the 
existence of an association between the pretreatment plasma 
Table III. Analysis using a Cox proportional hazards regres-
sion model for assessing the association between the plasma 
lactate dehydrogenase level and the overall survival.
Variable HR (95% CI) P-value
Stage  0.42
  III/IV 1.52 (0.56-4.80) 
  Recurrence 1
EGFR status  <0.01
  Common 0.14 (0.04-0.49) 
  Uncommon 1 
PS  0.03
  0-1 0.36 (0.14-0.89) 
  ≥2 1 
Pleural effusion  0.14
  Yes 1.97 (0.80-5.11) 
  No 1 
LDH  <0.01
  <210 0.27 (0.11-0.61) 
  ≥210 1
EGFR, epidermal growth factor receptor; LDH, lactate dehydro-
genase; PS, performance status; HR, hazard ratio; CI, confidence 
interval.
Table II. Analysis using a Cox proportional hazards regression 
model for assessing the association between the plasma lactate 
dehydrogenase level and progression-free survival.
Variable HR (95% CI) P-value
Stage  0.59
  III/IV 1.28 (0.53-3.31) 
  Recurrence 1
EGFR status  0.03
  Common 0.30 (0.11-0.90) 
  Uncommon 1
PS  0.28
  0-1 0.66 (0.32-1.40) 
  ≥2 1
Brain metastasis  <0.01
  Yes 3.39 (1.56-7.37) 
  No 1 
Liver metastasis  0.47
  Yes 1.32 (0.61-2.70) 
  No 1 
Pleural effusion  0.19
  Yes 1.74 (0.76-3.92) 
  No 1 
LDH  0.05
  <210 0.49 (0.24-0.99) 
  ≥210 1
EGFR, epidermal growth factor receptor; LDH, lactate dehydro-
genase; PS, performance status; HR, hazard ratio; CI, confidence 
interval.
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LDH level and survival in EGFR mutation-positive NSCLC 
patients receiving treatment with EGFR-TKIs, as previous 
studies had suggested the existence of a population with a 
poor prognosis even among these patients. Evaluation of the 
pretreatment plasma LDH level may contribute to follow-up 
planning in patients receiving treatment with EGFR-TKIs, and 
the establishment of a treatment strategy for the population 
with a poor prognosis is expected.
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